Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961763priorityCriticalpatent/ECSP961763A/en
Publication of ECSP961763ApublicationCriticalpatent/ECSP961763A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Indole Compounds
(AREA)
Abstract
Esta invención se refiere a inhibidores de la glucógeno fosforilasa, composiciones farmacéuticas que contienen tales inhibidores y al uso de tales inhibidores para tratar la diabetes, hiperglucemia, hipercoles terolemia, hipertensión, hiperinsulinemia, hiperlipidemia, ateroclerosis e isquemia de miocardio en mamíferos.This invention relates to glycogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors, and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholes, terolemia, hypertension, hyperinsulinemia, hyperlipidemia, atheroclerosis, and myocardial ischemia in mammals.
ECSP9617631996-05-291996-05-29
N- (INDOL -2-CARBONYL) GLYCINAMIDES SUBSTITUTED AND DERIVATIVES AS ANTIDIABETIC AGENTS
ECSP961763A
(en)
1,3-dihydroindol-2-one derivatives substituted at the 3-position with a nitrogen group for use as vasopressin and / or ocytocin agonists and / or antagonists
Compound, process for preparing the same, and use of it, pharmaceutical composition, and process for preparing the same, and process for effecting immunosuppression
N-sulfonyl-2-oxoindole derivatives having affinity for vasopressin and / or ocytocin receptors, pharmaceutical compositions containing them and intermediates in the preparation of the derivatives
N- (INDOL-2-CARBONYL) beta-ALANYLAMIDES SUBSTITUTED AND DERIVED AS INHIBITORS OF GLUCOGEN PHOSPHORYLASE, USE OF THE SAME AND COMPOSITIONS THAT CONTAIN THEM.
Pharmaceutical composition, processes for the treatment of a condition associated with reduced nicotine transmission, for the identification of a positive modulator of a nicotinic receptor agonist and for the identification of a compound, compound, and use of a positive modulator of a nicotinic receptor agonist